An FDA advisory board recommended withdrawing government approval for the breast cancer drug, Avastin. Pros and cons of the decision and its implications for FDA’s accelerated approval process to treat serious and life threatening diseases.


  • Dr. Peter Bach attending physician and director of the Center for Health Policy and Outcomes at Memorial Sloan-Kettering Cancer Center, and a former adviser to Medicare.
  • Dr. Carolyn Hendricks a medical oncologist affiliated with Suburban Hospital in Bethesda.
  • William Hubbard former associate commissioner for the Food and Drug Administration; spokesperson for the Alliance for a Stronger FDA
  • Gardiner Harris science reporter for "The New York Times" and author of the mystery novel 'Hazard.'

Topics + Tags


comments powered by Disqus
Most Recent Shows

AT&T’s Proposed Acquisition Of Time Warner

Tuesday, Oct 25 2016AT&T’s bid to acquire Time Warner: Join us to talk about what the proposed merger of the country’s second-largest wireless carrier and a major content company could mean for consumers and the future of U.S. media and telecommunications.

The State Of The Presidential Race

Monday, Oct 24 2016Early voting is underway in states across the country. Just over two weeks before the presidential election, a look at the latest polls, the electoral map and end-of-the-line strategies for both campaigns.